Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carotid Atherosclerosis
Conditions
Carotid Atherosclerosis
Trial Timeline
Apr 1, 2015 → —
NCT ID
NCT02532309About Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg is a approved stage product being developed by AstraZeneca for Carotid Atherosclerosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT02532309. Target conditions include Carotid Atherosclerosis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02532309 | Approved | UNKNOWN |
Competing Products
9 competing products in Carotid Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abciximab | Eli Lilly | Phase 1/2 | 41 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| simvastatin + placebo | Merck | Pre-clinical | 23 |
| Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin | Merck | Phase 2 | 52 |
| Evolocumab | Amgen | Approved | 84 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Rimonabant + Placebo (for Rimonabant) | Sanofi | Phase 3 | 76 |
| Gadobutrol (Gadovist, BAY86-4875) | Bayer | Phase 3 | 74 |